Organon & Co. is a global healthcare company dedicated to advancing women's health and providing access to essential medicines and health solutions
Focused on a broad range of therapeutic areas, Organon develops and offers a variety of pharmaceuticals, including contraceptives and treatments for conditions affecting women through different life stages. The company aims to address health inequalities and improve patient outcomes by emphasizing innovation and collaboration in the healthcare landscape. With a commitment to empowering women and enhancing their well-being, Organon seeks to create a positive impact on global health.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQCORT) and its peers.
This article covers three healthcare stocks that offer dividend yields of at least 7% and dives deeper into the fundamentals to determine if they're good buys.
Shares of pharmaceutical company Organon (NYSEOGN)
jumped 12.5% in the morning session after the company reported fourth-quarter 2024 results that topped analysts' revenue and EPS expectations. While sales were flat year on year, strength in Established Brands helped offset declines in Biosimilars and Women's Health.
However, the company's full-year revenue outlook came in lower than expected, reflecting headwinds from foreign exchange and the loss of exclusivity for Atozet (the second-largest product) in key markets.
Overall, this quarter was decent, but not perfect.
Pharmaceutical company Organon (NYSEOGN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales were flat year on year at $1.59 billion. On the other hand, the company’s full-year revenue guidance of $6.23 billion at the midpoint came in 3.2% below analysts’ estimates. Its non-GAAP profit of $0.90 per share was 3.9% above analysts’ consensus estimates.
Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Nippon Shinyaku will pay $20 million upfront and up to $715 million in milestones, plus royalties.
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2 billion.
